DOI:
10.1055/s-00000069
Seminars in Liver Disease
LinksClose Window
References
Herraez E, Lozano E, Macias RI. et al.
Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.
Hepatology 2013;
58 (03) 1065-1073
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.